Evidence map›Paper›PMID 39928533›Full record

ArticleClinical and translational science2025

Pharmacokinetics and ADME Characterization After Oral and Intravenous Administration of [

Amitava Mitra, Julie Mackey Ahsan, Marilyn Tabachri, Taha El-Shahat, Mollie Leoni, Stephen Dale

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amitava MitraClinical Pharmacology, Kura Oncology, Inc., San Diego, California, USA.
Julie Mackey AhsanClinical Development, Kura Oncology, Inc., San Diego, California, USA.
Marilyn TabachriClinical Development, Kura Oncology, Inc., San Diego, California, USA.
Taha El-ShahatClinical Pharmacology Services, Fortrea, Madison, Wisconsin, USA.ORCID 0009-0000-2885-0902
Mollie LeoniClinical Development, Kura Oncology, Inc., San Diego, California, USA.
Stephen DaleClinical Development, Kura Oncology, Inc., San Diego, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ziftomenib, a potent, selective inhibitor that binds menin at the lysine methyltransferase 2 interaction site, has demonstrated promising clinical activity with manageable toxicity in heavily pretreated patients with acute myeloid leukemia (AML) and nucleophosmin 1 mutations. This phase 1, open-label study characterized the absorption, metabolism, excretion, and bioavailability of ziftomenib in healthy men and comprised two parts. In part A, a single oral dose of ziftomenib 400 mg (containing 250 μCi [

Indexed as

Antineoplastic AgentsProto-Oncogene ProteinsAdministration, IntravenousAdministration, OralAdultBiological AvailabilityCarbon RadioisotopesFecesHealthy VolunteersHumansLeukemia, Myeloid, AcuteMaleMiddle AgedYoung AdultAntineoplastic AgentsCarbon RadioisotopesMEN1 protein, humanProto-Oncogene Proteinsabsorptionbioavailabilitydosehealthy subjectsinhibitorsmetabolismpharmacokinetics–pharmacodynamicsphase Isafetytherapeutics

Identifiers

PMID39928533
PMCPMC11809555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.